Discover

SPRY
ARS Pharmaceuticals, Inc.
4.11
2 x 3.89
2 x 6.72
bid
ask
-
0.04
0.96%
2 @ 04:00 PM
4.11 +0.00 (0.00%)
Ytd-64.72%
1y-58.61%
4.10
day range
4.20
4.10
52 week range
13.15
Open4.10Prev Close4.15Low4.10High4.20Mkt Cap408.73M
Vol1.89MAvg Vol2.06MEPS-2.18P/EN/AForward P/E-11.01
Beta0.83Short Ratio13.70Inst. Own95.47%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-1050-d Avg5.82200-d Avg8.401yr Est28.80

SPRY News

SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
newsfilecorp.com
SPRY UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Cla

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
globenewswire.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc.

NEW YORK, Sept. 18, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
globenewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS

LOS ANGELES, Sept. 18, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national sha

SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
newsfilecorp.com
SPRY SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Secu

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on October 5, 2026
newsfilecorp.com
Kaplan Fox Alerts ARS Pharmaceuticals Inc. (SPRY) Investors to the Lead Plaintiff Deadline on Octobe

New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP announces th

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action File

NEW YORK, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should Contact SueWallSt
prnewswire.com
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors Should

A securities class action traces ARS Pharmaceuticals' alleged March-to-June 2026 disclosure sequence

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - SPRY
prnewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmace

NEW YORK, Sept. 17, 2026 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has bee

SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
prnewswire.com
SPRY Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud La

NEW YORK, Sept. 16, 2026 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds

Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Before October 5, 2026
newsfilecorp.com
Kaplan Fox Urges ARS Pharmaceuticals Inc. (SPRY) Investors Seeking Recovery to Contact the Firm Befo

New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP announces th

SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Class Action Deadline
prnewswire.com
SPRY DEADLINE: Levi & Korsinsky Reminds ARS Pharmaceuticals Inc. Investors of Upcoming Securities Cl

A securities class action alleges ARS Pharmaceuticals overstated its progress toward removing prior

SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
newsfilecorp.com
SPRY SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Cl

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – SPRY
globenewswire.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ARS Pharmace

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has

ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SPRY
globenewswire.com
ARS PHARMACEUTICALS DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc.

NEW YORK, Sept. 15, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm,

Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors
globenewswire.com
Portnoy Law Firm Announces Class Action on Behalf of ARS Pharmaceuticals, Inc. Investors

LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises ARS Pharmaceuticals, In

SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Losses May Contact SueWallSt
globenewswire.com
SPRY Shareholder Alert: ARS Pharmaceuticals Inc. Securities Class Action Lawsuit - Investors With Lo

A securities class action alleges ARS Pharmaceuticals' co-founder and CEO personally steered investo

SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
globenewswire.com
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS

LOS ANGELES, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Schall, Brown & Schwartz LLP (“SBS”), a national sha

LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares - Purchased Between March and June 2026 - Should Contact the Shareholders Foundation
businesswire.com
LAWSUIT ALERT: Investors Who Lost Over $100,000 With ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) Shares

SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announces that a deadline is coming up

Kaplan Fox Advises ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Deadline on October 5, 2026
newsfilecorp.com
Kaplan Fox Advises ARS Pharmaceuticals Inc. (SPRY) Investors of a Securities Class Action Deadline o

New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP announces th

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmaceuticals Inc. Lawsuit - SPRY
globenewswire.com
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 5, 2026 in ARS Pharmac

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in ARS Pharmaceu

Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action Filed Alleging Investor Harm
globenewswire.com
Bronstein, Gewirtz & Grossman LLC Urges ARS Pharmaceuticals Inc. Investors to Act: Class Action File

NEW YORK, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Bronstein, Gewirtz & Grossman, LLC, a nationally recogn

SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
newsfilecorp.com
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securitie

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suff